Belpaire F M, Van de Velde E J, Fraeyman N H, Bogaert M G, Lameire N
Heymans Institute of Pharmacology, University of Gent Medical School, Belgium.
Eur J Clin Pharmacol. 1988;35(4):339-43. doi: 10.1007/BF00561361.
The influence of continuous ambulatory peritoneal dialysis (CAPD) on the concentrations of alpha 1-acid glycoprotein in serum and dialysate and on the serum binding of oxprenolol, propranolol and phenytoin has been studied. Before starting CAPD treatment, the serum binding of oxprenolol and propranolol was higher and that of phenytoin lower than in healthy volunteers, and the serum alpha 1-AGP concentration was higher. During the first days to weeks after starting CAPD, the serum alpha 1-AGP concentration rose with a concomitant increase in the binding of oxprenolol and propranolol. Subsequently, the alpha 1-AGP level and the binding of oxprenolol and propranolol decreased to the values found before starting CAPD. The binding of phenytoin showed little change. The concentration of alpha 1-AGP in dialysate was 2 to 5% of that in serum.
研究了持续性非卧床腹膜透析(CAPD)对血清和透析液中α1-酸性糖蛋白浓度以及对氧烯洛尔、普萘洛尔和苯妥英血清结合率的影响。在开始CAPD治疗前,氧烯洛尔和普萘洛尔的血清结合率高于健康志愿者,而苯妥英的血清结合率低于健康志愿者,且血清α1-AGP浓度较高。在开始CAPD后的最初几天至几周内,血清α1-AGP浓度升高,同时氧烯洛尔和普萘洛尔的结合率增加。随后,α1-AGP水平以及氧烯洛尔和普萘洛尔的结合率降至开始CAPD前的水平。苯妥英的结合率变化不大。透析液中α1-AGP的浓度为血清中的2%至5%。